1 / 16

Teva Pharmaceutical Industries (TEVA)

Analyst: Ryan Youngstrand Saturday, September 5, 2009. Teva Pharmaceutical Industries (TEVA). Stock Price $51.16 52-week range $35.89-54.95 Beta 0.14 EPS (TTM) $1.10. TEVA currently (Yahoo! Finance). Sector: Healthcare Industry : Drug Manufacturers – Other

jagger
Download Presentation

Teva Pharmaceutical Industries (TEVA)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Analyst: Ryan Youngstrand Saturday, September 5, 2009 Teva Pharmaceutical Industries (TEVA)

  2. Stock Price • $51.16 • 52-week range • $35.89-54.95 • Beta • 0.14 • EPS (TTM) • $1.10 TEVA currently (Yahoo! Finance)

  3. Sector: Healthcare Industry : Drug Manufacturers – Other “The company was founded in 1901 and is headquartered in Petach Tikva, Israel” (Yahoo! Finance). “…engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide” (Yahoo! Finance). What they do…

  4. “…principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson’s disease” (Yahoo! Finance). “…also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler, and Cyclohaler, a single dose dry powder device” (Yahoo! Finance). “It has a collaboration agreement with Optimata Ltd. To develop solid tumor cancer drugs; a strategic alliance with Kowa Company, Ltd. to establish a generic pharmaceutical company in Japan; and a strategic partnership with the Lonza Group in a joint venture to develop, manufacture, and market a portfolio of biogenerics” (Yahoo! Finance). What they do…

  5. Swot analysis • Strengths: • Good Potential for Growth • International Company • Products Necessities • Sheltered from the economic condition. • Weaknesses: • Since it is an international company, international risk exists (exchange rates, international and trade laws, etc.).

  6. Swot analysis • Opportunities: • The growing opportunity for biogeneric products and services. • Threats • Competition • International Risk • Recalls

  7. Financial ratios (Reuters)

  8. Financial ratios cont’d (Reuters)

  9. Valuation ratios (Reuters)

  10. Trend analysis (Morningstar)

  11. TTM = 635.0 2008 = 635.0 2007 = 1,952.0 2006 = 546.0 2005 = 1,072.3 2004 = 331.8 2003 = 691.0 2002 = 410.3 2001 = 278.2 2000 = 148.4 1999 = 117.8 Net income ($mil)

  12. EPS from Net Income • TTM = 0.78 • 2008 = 0.78 • 2007 = 2.38 • 2006 = 0.69 • 2005 = 1.59 • 2004 = 0.50 • 2003 = 1.20 • 2002 = 0.76 • 2001 = 0.51 • 2000 = 0.29 • 1999 = 0.24 EPS ($MIL)

  13. PEG (5 Yr. Expected) = 0.88 Market Cap = 44.71B PEGY = -8.14 EPS Growth = -7.69 Current Ratio = 1.52 P/E = 54.6 ROE = 4.23% ROA = 2.26% teva now

  14. 2-YEAR STOCK CHART

  15. COMPARISON WITH COMPETITORS AND S&P 500

  16. HOLD (Growth, Large Cap Stock) Recommendation

More Related